Boehringer Ingelheim Enters the Clinic with Two New Diabetes Drugs

Boehringer Ingelheim starts two new Phase I trials with drugs intended to treat type 2 diabetes and obesity discovered through a partnership with Danish biotech Zealand. 

The new Phase I trials initiated by Boehringer Ingelheim will be conducted in Germany, with results expected at the end of 2018. The drugs evaluated will be a long-acting amylin analog and a dual agonist of glucagon and GLP-1, both intended to improve the control of blood sugar levels in patients with type 2 diabetes and diabetes.

The drugs come from two ongoing research collaborations between Boehringer Ingelheim and the diabetes specialist Zealand Pharma, which will receive a €4M milestone payment following the start of clinical trials with the amylin analog. Together, both agreements sum €648M in outstanding milestone payments for the Danish biotech, plus royalties on future sales.

Zealand is experienced in the development of diabetes drugs for big pharma, including two GLP-1 drugs for Sanofi that are already in the market. For more info on new treatments for diabetes, including the popular GLP-1, read our review.


Image via Room’s Studio / Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.

We use cookies to give you the best experience. If you click on accept, we also use tracking cookies for analytics and advertising purposes. Check our privacy policy for more details. By accepting, you support our independent media and its’ freely accessible content. You may withdraw your consent at any time.